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Abstract 
The results reported in this thesis comprise an investigation into the conjugation of 
insulin to oxidized dextran, various release studies from the conjugates, and an attempt 
to interpret the binding nature of the conjugates. A model system involving the 
sustained release from insulin-dextran conjugates has been employed in this study. For 
insulin , up to 3 potential sites only (Al-Gly, Bl-Phe and B29-Lys) were expected to 
bind to oxidized dextran. The rate of release and the maintenance of activity of the 
released protein are vital to such systems. Success in the interpretation of the binding 
nature of the conjugate will allow us to investigate its relationship to the rate of release. 
The desired rate of release for the sustained release of protein could then be achieved, 
once the projected binding could be obtained. 
Activation of dextran was achieved by periodate oxidation to give levels of 8%, 16% 
and 27% oxidized dextran. Insulin was chosen for its relatively 'uncomplicated' 
structure and few _ possible sites available for binding with activated dextran. Insulin 
was bound to the dextran through imine bonds. Complex formation was examined 
under a wide range of conditions. Initial studies were begun with the determination of a 
desirable basic molar ratio. A molar ratio of insulin to 8% activated dextran of 10 : 1 
arose from this set of experiments. Insulin was bound to 27% activated dextran at pH 
7.4, pH 9 and pH 10. In the cases of pH 9 and pH 10, many more lower MW 
complexes were formed than at pH 7.4. It seemed that the higher the pH of formation, 
the more crosslinks occurred between an insulin molecule and dextran molecules in the 
lower MW range. Approximate physiological pHs (pH 7.1-7.8) were used for complex 
formation in all subsequent experiments. 
Release studies were carried out under approximate physiological conditions (pH 7.4, 
37°C). Immediate release was observed upon isolation by size exclusion 
chromatography. The greatest release occurred in the first 24 hours for all three 
activation levels. The higher the activation level of dextran, the lower the level of 
release. An equilibrium was established after several days' release and studies at 37°C 
produced the expected result: greater release relative to ambient. 
A number of studies were carried out with complex after sodium cyanoborohydride had 
been used to reduce the imine bonds. 
Ill 
The first set of experiments on the reduced complexes was enzymatic cleavage studies, 
which employed trypsin and a-chymotrypsin. The results for trypsin digestion of the 
reduced insulin-27% oxidized dextran complex indicated partial binding had occurred 
at B29-Lys, in combination with full binding at Bl and/or Al. Amino acid analysis 
results of the isolated complex after trypsin digestion indicated about 90% binding 
occurred at B29-Lys for the complex, which formed at pH 7.1. The results of a-
chymotrypsin digestion study were shown questionable due to its incomplete cleavage. 
The reduced complexes were analyzed by ammo acid analysis. The insulin-27% 
activated dextran complexes formed at pH 7.4, pH 9 and pH 10 showed similar extents 
of binding at B 1-Phe, indicating B 1 might be the prime binding site. There was more 
binding at B29 and A I for the pH 9 than at pH 7.4 case. At pH IO abnormal values 
arose. The studies for the complexes of insulin with 16% and 27% activated dextran 
indicated the more highly activated the dextran , the greater the binding at B29 and A 1. 
Trials with the 2, 4-dinitrophenyl-derivativatization method proved to be a useful way 
to examine the degree of B 1 and B29 binding from the amino acid analysis results of 
complex . The insulin-16% activated dextran complex formed at pH 7.1 was found to 
be about 100% binding at BI , 60% at A 1 and 50% at B29. 
Oxidative and reductive cleavage studies of A and B chains of insulin and the complex 
were carried out to investigate the level of A 1 binding. After chemical cleavage of the 
three disulfide bonds in insulin and subsequent chromatography, the amino acid 
--analysi s- resuhs fo r---the-t-reated eomplexes ind-icated a sign~f'icant propoi=t-i0n of A chain 
had bound to dextran, i.e. at Al . An estimation of 60-70% of Al binding was achieved 
for this study. 
This exploratory study has shown that varied complex formation conditions such as the 
level of activation of dextran, pH, and temperature could alter the extent of binding 
between insulin and dextran molecules. Amino acid analysis of the reduced complex 
was a useful method to interpret the binding. 
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